PCM
XFOR icon

Prelude Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Prelude Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,503
Closed -$70.3K – 1598
2024
Q3 		$70.3K Sell
3,503
-1,943
-36% -$40.5K ﹤0.01% 1191
2024
Q2 		$94.8K Buy
+5,446
New +$178K 0.01% 1103
2020
Q4 		– Sell
-64
Closed -$13K – 2075
2020
Q3 		$13K Buy
64
+61
+2,033% +$14.6K ﹤0.01% 1417
2020
Q2 		$1K Buy
+3
New +$821 ﹤0.01% 1894
2020
Q1 		– Sell
-7
Closed -$2K – 2107
2019
Q4 		$2K Buy
+7
New +$2.51K ﹤0.01% 1838

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's XFOR Position: Q4 2024 in Review

Prelude Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 3,503 shares — an estimated $70.3K sold.

Prelude Capital Management first reported a position in XFOR in Q4 2019 and held it in 5 quarters. The position peaked at $94.8K in Q2 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Prelude Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 3,503 X4 Pharmaceuticals shares in Q4 2024, an estimated $70.3K.
  • Prelude Capital Management first reported a position in X4 Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Prelude Capital Management's X4 Pharmaceuticals position peaked at $94.8K in Q2 2024.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.